28.98
price up icon1.29%   0.375
after-market Handel nachbörslich: 29.00 0.015 +0.05%
loading
Schlusskurs vom Vortag:
$28.61
Offen:
$28.54
24-Stunden-Volumen:
1.87M
Relative Volume:
1.12
Marktkapitalisierung:
$5.14B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
14.86
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-1.26%
1M Leistung:
-5.33%
6M Leistung:
+0.76%
1J Leistung:
+18.82%
1-Tages-Spanne:
Value
$28.48
$30.00
1-Wochen-Bereich:
Value
$28.48
$30.00
52-Wochen-Spanne:
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Firmenname
Alkermes Plc
Name
Telefon
00-353-1-772-8000
Name
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Name
Mitarbeiter
1,800
Name
Twitter
@alkermes
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
ALKS's Discussions on Twitter

Vergleichen Sie ALKS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
28.98 5.14B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
14.60 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.19 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.36 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.37 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.65 20.17B 16.54B -1.64B 749.00M -1.45

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-28 Eingeleitet Needham Buy
2025-03-13 Eingeleitet RBC Capital Mkts Sector Perform
2025-03-04 Hochstufung UBS Sell → Neutral
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-11-05 Hochstufung Stifel Hold → Buy
2024-06-17 Eingeleitet TD Cowen Buy
2024-03-19 Eingeleitet Robert W. Baird Outperform
2024-02-20 Herabstufung UBS Neutral → Sell
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-10-24 Hochstufung Evercore ISI In-line → Outperform
2023-10-17 Eingeleitet UBS Neutral
2022-11-03 Hochstufung Piper Sandler Neutral → Overweight
2022-10-14 Hochstufung BofA Securities Underperform → Neutral
2022-08-16 Eingeleitet Piper Sandler Neutral
2022-04-22 Fortgesetzt Goldman Buy
2022-04-20 Eingeleitet Goldman Buy
2022-01-27 Hochstufung Cantor Fitzgerald Hold → Overweight
2021-12-01 Eingeleitet Citigroup Neutral
2021-10-07 Hochstufung Jefferies Hold → Buy
2021-09-02 Herabstufung BofA Securities Neutral → Underperform
2020-10-15 Hochstufung Mizuho Neutral → Buy
2020-07-30 Herabstufung Goldman Neutral → Sell
2020-02-14 Herabstufung BofA/Merrill Buy → Neutral
2020-02-14 Bestätigt H.C. Wainwright Neutral
2020-02-14 Herabstufung JP Morgan Overweight → Neutral
2020-02-06 Eingeleitet Mizuho Neutral
2020-01-31 Hochstufung Wolfe Research Underperform → Peer Perform
2019-09-05 Hochstufung Morgan Stanley Underweight → Equal-Weight
2019-07-15 Hochstufung Goldman Sell → Neutral
2019-05-31 Eingeleitet H.C. Wainwright Neutral
2019-05-01 Herabstufung Citigroup Buy → Neutral
2018-12-19 Herabstufung Goldman Neutral → Sell
2018-12-14 Eingeleitet Wolfe Research Underperform
2018-12-13 Herabstufung Credit Suisse Outperform → Underperform
2018-11-05 Eingeleitet Piper Jaffray Neutral
2018-08-07 Eingeleitet Stifel Hold
2018-06-21 Herabstufung Morgan Stanley Equal-Weight → Underweight
2018-06-06 Eingeleitet B. Riley FBR, Inc. Buy
2018-05-16 Hochstufung Citigroup Neutral → Buy
2018-05-11 Eingeleitet BofA/Merrill Buy
Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

pulisher
Jun 18, 2025

Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narcolepsy Treatment | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 12, 2025

When (ALKS) Moves Investors should Listen - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Substance Abuse Treatment Market Size, Trends & Growth - openPR.com

Jun 12, 2025
pulisher
Jun 10, 2025

Insider Sell: Christian Nichols Sells Shares of Alkermes PLC - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

RBC Capital maintains Alkermes stock rating amid safety concerns By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

GAMMA Investing LLC Grows Position in Alkermes plc (NASDAQ:ALKS) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Alkermes plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Alkermes To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 09, 2025
pulisher
Jun 06, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award - Law360

Jun 06, 2025
pulisher
Jun 05, 2025

Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com

Jun 05, 2025
pulisher
Jun 04, 2025

Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve

Jun 03, 2025
pulisher
Jun 02, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - StreetInsider

Jun 02, 2025
pulisher
Jun 02, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com

Jun 02, 2025
pulisher
May 31, 2025

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st

May 31, 2025
pulisher
May 31, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World

May 31, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - goSkagit

May 29, 2025
pulisher
May 29, 2025

Global Healthcare & Medical Tourism News - Medical Tourism Magazine

May 29, 2025
pulisher
May 28, 2025

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World

May 27, 2025
pulisher
May 23, 2025

Controlled Release Drug Delivery Market Generated - openPR.com

May 23, 2025
pulisher
May 23, 2025

Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

May 23, 2025
pulisher
May 21, 2025

Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks

May 21, 2025
pulisher
May 20, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

May 20, 2025

Finanzdaten der Alkermes Plc-Aktie (ALKS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alkermes Plc-Aktie (ALKS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$14.44
price up icon 1.09%
$9.18
price up icon 2.80%
$128.04
price up icon 1.87%
$290.91
price up icon 1.14%
drug_manufacturers_specialty_generic RDY
$14.94
price down icon 0.60%
$16.65
price down icon 0.63%
Kapitalisierung:     |  Volumen (24h):